west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "NK/T细胞淋巴瘤" 3 results
  • Aggressive NK/T Lymphoma with Autologous Hematopoietic Stem Cell Transplantation

    【摘要】 目的 探讨自体造血干细胞移植(autologous hematopoietic stem cell transplantation,auto-HSCT)治疗侵袭性NK/T细胞淋巴瘤的疗效。 方法 对我科2005年1月16日收治的1例侵袭性NK/T细胞淋巴瘤患者的造血干细胞移植和随访资料进行回顾性分析,并复习国内外相关文献。 结果 患者为37岁女性,诊断结外鼻型NK/T细胞淋巴瘤,系统性,经CHOAP和ICE方案化学疗法、手术、局部放射治疗控制病情良好后,采集自体骨髓造血干细胞,行auto-HSCT,预处理方案为全身放射治疗+ECy;移植+29 d造血功能即顺利重建;移植后密切随访,患者一直处于完全缓解,至今已存活67个月。 结论 auto-HSCT治疗侵袭性NK/T细胞淋巴瘤疗效肯定、可靠。【Abstract】 Objective To explore the therapeutic effect of autologous hematopoietic stem cell transplantation (auto-HSCT) on aggressive NK/T lymphoma. Methods The clinical data of one patient with aggressive NK/T lymphoma diagnosed in January 2005 were retrospectively analyzed, and the relevant domestic literatures were analyzed. Results This thirty-seven-year-old female patient had good disease control after undergoing chemotherapy with CHOAP and ICE regimens, surgery, and locoregional radiotherapy. After that, she had been collected enough bone marrow-derived hematopoietic stem cells, then underwent auto-HSCT with these cells. The conditioning regimen was TBI plus ECy. On the +29th day after transplantation,the hematopoietic reconstruction was successful. During the follow-up period, the patient was in complete remission status all along and her disease-free survival (DFS) was 67 months. Conclusion Auto-HSCT is effective on aggressive NK/T lymphoma.

    Release date:2016-08-26 02:18 Export PDF Favorites Scan
  • 原钙粘蛋白15在NK/T细胞淋巴瘤诊断中的价值

    原钙粘蛋白15(PCDH15),作为钙粘蛋白超家族的成员,在人类由位于10号染色体q21的PCDH15基因编码,它包括11个重复胞外钙结合结构域、一个跨膜区和一个独特的胞质域,分为四个亚型:PCDH15-CD1、CD2、CD3和不含跨膜区与胞浆区的PCDH15-SI亚型。在YT型NK/T淋巴瘤细胞株研究中发现的PCDH15-SI亚型,其结构和功能与以往所知的PCDH15有很大差异,在正常T、B及NK淋巴细胞及其活化后均不表达,而在NK/T细胞淋巴瘤特异表达。这一发现有可能让PCDH15-SI型成为NK/T细胞淋巴瘤诊断中的有价值的新的生物标记。

    Release date: Export PDF Favorites Scan
  • 皮肤NK/T细胞淋巴瘤的治疗与研究现状

    结外鼻型NK/T细胞淋巴瘤(ENKTCL)是一种少见疾病,其分布具有明显的地域和种族特征,西方国家比较少见,多发生于亚洲、墨西哥及中南美洲,占所有非霍奇金淋巴瘤的5%~18%。按解剖部位被划分为上呼吸消化道NK/T细胞淋巴瘤(UAT-NKTCL)和非上呼吸消化道NK/T细胞淋巴瘤(NUAT-NKTCL)。在非上呼吸消化道病例中,皮肤往往是瘤体最常侵犯的器官。皮肤受累的结外鼻型NK/T细胞淋巴瘤称为皮肤NK/T细胞淋巴瘤(CNKTCL),包括了原发于皮肤以及原发于皮肤外的晚期ENKTCL皮肤浸润,但是不论是疾病原发或是继发的晚期皮肤浸润,其病程进展快,预后差,中位生存时间<12个月。侵袭性淋巴瘤常用的化学疗法方案如CHOP(环磷酰胺+多柔比星+长春新碱+泼尼松)或者CHOP类似方案以及对鼻部早期患者证实有效的局部放射治疗在皮肤NK/T患者中并未带来明显的生存获益,目前新的治疗方案还在探索中。随着肿瘤分子生物学的标靶干预和基因组研究的深入进展,靶向治疗有望为CNKTCL患者带来福音。本文将着重就CNKTCL治疗现状和预后加以综述。

    Release date:2016-09-08 09:11 Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content